company background image
1760 logo

Panion & Bf Biotech TWSE:1760 Stock Report

Last Price

NT$83.30

Market Cap

NT$7.0b

7D

1.5%

1Y

-20.7%

Updated

08 Jan, 2025

Data

Company Financials +

Panion & Bf Biotech Inc.

TWSE:1760 Stock Report

Market Cap: NT$7.0b

1760 Stock Overview

A biotechnology pharmaceutical company, provides western medicines, cosmetics, and health care products in Taiwan, the United States, China, Hong Kong, and internationally. More details

1760 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends3/6

My Notes

Capture your thoughts, links and company narrative

Panion & Bf Biotech Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Panion & Bf Biotech
Historical stock prices
Current Share PriceNT$83.30
52 Week HighNT$115.00
52 Week LowNT$76.20
Beta0.25
1 Month Change-3.36%
3 Month Change-6.09%
1 Year Change-20.67%
3 Year Change2.33%
5 Year Change-3.03%
Change since IPO635.50%

Recent News & Updates

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Aug 13
Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Recent updates

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Aug 13
Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Apr 07
Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Mar 03
Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

Feb 04
Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

Jan 09
Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Dec 14
Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Shareholder Returns

1760TW PharmaceuticalsTW Market
7D1.5%-0.1%2.5%
1Y-20.7%1.6%32.2%

Return vs Industry: 1760 underperformed the TW Pharmaceuticals industry which returned 1.6% over the past year.

Return vs Market: 1760 underperformed the TW Market which returned 32.2% over the past year.

Price Volatility

Is 1760's price volatile compared to industry and market?
1760 volatility
1760 Average Weekly Movement3.1%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement4.4%
10% most volatile stocks in TW Market7.8%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 1760 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 1760's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1974n/aTsung-Ming Chiangwww.pbf.com.tw

Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, provides western medicines, cosmetics, and health care products in Taiwan, the United States, China, Hong Kong, and internationally. The company offers products in the areas of antibody, respiratory, gastrointestinal, Covid-19 IVD, antigen, anti-aging, active pharmaceutical ingredients, disease treatment, prevention, and veterinary products. It also offers nephrology, dermatology, pain management, hospital and household sanitization, and personal hygiene services.

Panion & Bf Biotech Inc. Fundamentals Summary

How do Panion & Bf Biotech's earnings and revenue compare to its market cap?
1760 fundamental statistics
Market capNT$7.04b
Earnings (TTM)NT$121.33m
Revenue (TTM)NT$2.04b

58.9x

P/E Ratio

3.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1760 income statement (TTM)
RevenueNT$2.04b
Cost of RevenueNT$968.40m
Gross ProfitNT$1.07b
Other ExpensesNT$946.04m
EarningsNT$121.33m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.42
Gross Margin52.43%
Net Profit Margin5.96%
Debt/Equity Ratio36.8%

How did 1760 perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

106%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 07:54
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Panion & Bf Biotech Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jianzheng WuCapital Securities Corporation
Xiaowei HuangMasterlink Securities Corp.
Jane JiangYuanta Research